• Home
  • Search Results
  • Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis.

Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis.

The Journal of infectious diseases (2013-08-01)
Monique van Velzen, David A M C van de Vijver, Freek B van Loenen, Albert D M E Osterhaus, Lies Remeijer, Georges M G M Verjans

Long-term acyclovir (ACV) prophylaxis, recommended to prevent recurrent herpes simplex virus type 1 (HSV-1) ocular disorders, may pose a risk for ACV-refractory disease due to ACV resistance. We determined the effect of ACV prophylaxis on the prevalence of corneal ACV-resistant (ACV(R)) HSV-1 and clinical consequences thereof in patients with recurrent HSV-1 keratitis (rHK). Frequencies of ACV(R) viruses were determined in 169 corneal HSV-1 isolates from 78 rHK patients with a history of stromal disease. The isolates' ACV susceptibility profiles were correlated with clinical parameters to identify risk factors predisposing to ACV(R) rHK. Corneal HSV-1 isolates with >28% ACV(R) viruses were defined as ACV(R) isolates. Forty-four isolates (26%) were ACV-resistant. Multivariate analyses identified long-term ACV prophylaxis (≥12 months) (odds ratio [OR] 3.42; 95% confidence interval [CI], 1.32-8.87) and recurrence duration of ≥45 days (OR 2.23; 95% CI, 1.02-4.87), indicative of ACV-refractory disease, as independent risk factors for ACV(R) isolates. Moreover, a corneal ACV(R) isolate was a risk factor for ACV-refractory disease (OR 2.28; 95% CI, 1.06-4.89). The data suggest that long-term ACV prophylaxis predisposes to ACV-refractory disease due to the emergence of corneal ACV(R) HSV-1. ACV-susceptibility testing is warranted during follow-up of rHK patients.

Product Number
Product Description

Acyclovir, Pharmaceutical Secondary Standard; Certified Reference Material
Acycloguanosine, ≥99% (HPLC), powder
Aciclovir, European Pharmacopoeia (EP) Reference Standard